Semaglutide and GLP-1 Therapy in Ontario: A Physician’s Framework

GLP-1 receptor agonists are among the most consequential pharmaceutical developments of the past decade. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) have produced weight loss and metabolic outcomes that diet and exercise alone rarely match. The clinical evidence is large, recent, and strong.

The marketing around them has been less measured. Patients in Ontario are now offered GLP-1 therapy through clinics ranging from medical practices that monitor properly to online services that ship vials with minimal physician contact. The treatment can be transformative, or it can be inadequately supervised. The difference is the framework.

This is a physician’s view of when GLP-1 therapy is appropriate, what monitoring is required, and how it should fit into the broader picture of metabolic health.

What GLP-1 Receptor Agonists Actually Do

GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone secreted by the small intestine in response to food. It slows gastric emptying, increases satiety, suppresses inappropriate glucagon release, and amplifies insulin secretion in a glucose-dependent manner. The endogenous half-life is short — minutes — which limits its therapeutic utility in its native form.

Semaglutide and tirzepatide are modified peptides engineered to resist enzymatic degradation, extending the half-life to roughly one week. They bind to and activate the GLP-1 receptor (and, in the case of tirzepatide, the GIP receptor as well), producing sustained satiety, slowed gastric emptying, and improved glycemic control.

The downstream effects observed in clinical trials are substantial. Mean weight loss of fifteen to twenty percent of baseline body weight at one year. Reduction in HbA1c of one to two percentage points in patients with type 2 diabetes. The SELECT trial, published in 2023, demonstrated a twenty percent reduction in major adverse cardiovascular events with semaglutide in non-diabetic adults with established cardiovascular disease and obesity, a finding that elevates GLP-1 therapy from a weight-loss tool to a cardiovascular intervention.

These are not marginal effects. They are clinically meaningful and, for many patients, durable while treatment continues.

When GLP-1 Therapy Is Appropriate

The question is not whether GLP-1 therapy works. The question is for whom, and under what conditions.

The Health Canada indications cover type 2 diabetes (semaglutide as Ozempic, Rybelsus; tirzepatide as Mounjaro) and chronic weight management at specific BMI thresholds with or without weight-related comorbidities (semaglutide as Wegovy; tirzepatide as Zepbound).

In a functional medicine context, the decision matrix is more nuanced. The presence of insulin resistance, fasting insulin elevation, central adiposity, hepatic steatosis, or metabolic syndrome criteria is more clinically relevant than BMI alone. A patient with normal BMI but a fasting insulin of fifteen and a visceral fat percentage above target is metabolically dysfunctional and may benefit from intervention. A patient at the formal obesity threshold whose insulin sensitivity, lipid profile, and inflammatory markers are well controlled may not require pharmacotherapy.

The decision rests on a comprehensive metabolic evaluation — fasting insulin, HOMA-IR, HbA1c, ApoB, hs-CRP, ALT, body composition — rather than on weight in isolation.

What Monitoring Should Look Like

GLP-1 therapy is not a prescription that can responsibly be issued and forgotten. The monitoring obligations include:

Baseline: A complete metabolic panel including fasting insulin, HOMA-IR, HbA1c, lipid panel with ApoB, liver enzymes, kidney function, and TSH. Body composition assessment when available. Documentation of personal and family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2 (contraindications). Pancreatic history. Documentation of weight, blood pressure, and waist circumference.

During titration: Standard semaglutide titration starts at 0.25 mg weekly and increases monthly to a target dose, typically 1.0, 1.7, or 2.4 mg, based on tolerance and response. Tirzepatide titration follows a similar pattern. Symptom check-ins through the titration phase identify gastrointestinal intolerance, gallbladder symptoms, and rare but important adverse events. Most side effects — nausea, constipation, fatigue — improve with slower titration.

Ongoing: Quarterly to twice-yearly bloodwork to track metabolic response, monitor for muscle mass loss (lean mass preservation is a clinical priority), and reassess whether the dose is still appropriate. Body composition reassessment when feasible. Continued attention to nutrition adequacy — protein intake of 1.2 to 1.6 grams per kilogram of body weight is the floor most patients need to preserve muscle while in caloric deficit. Resistance training is non-negotiable.

This kind of monitoring is the difference between using GLP-1 therapy as a metabolic intervention and using it as a weight-loss prescription. The former preserves health span. The latter risks losing muscle, bone, and metabolic resilience along with the fat.

Brand-Name vs. Compounded Preparations

This is the area where the Ontario market has become most complicated.

Brand-name semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are pharmaceutical-grade preparations manufactured by Novo Nordisk and Eli Lilly respectively. They are dispensed through licensed pharmacies, with quality control, lot tracking, and pharmacovigilance.

Compounded semaglutide is a different product. During the period when Health Canada listed semaglutide on the drug shortage list, certain licensed compounding pharmacies were permitted to prepare semaglutide for individual patients to address legitimate clinical need. The shortage status changes over time and varies by formulation. Compounded preparations are not generic equivalents; they are pharmacy-prepared products under specific regulatory conditions.

A patient considering compounded GLP-1 therapy should ask several questions. Is the pharmacy licensed and inspected? Is the active ingredient sourced from a regulated supplier? Is the preparation tested for potency and sterility? Is the prescribing physician monitoring the patient on the same schedule as for brand-name therapy? Does the compounded preparation match the dosing scheme of the studied product?

Manus Solis works with Trutina, our Ontario compounding pharmacy partner, when compounded preparations are clinically and regulatorily appropriate, and refers to brand-name preparations through standard pharmacy channels otherwise. The choice is driven by what is best and most appropriate for the patient, not by what is most convenient or profitable for the practice.

Where GLP-1 Therapy Fits in the Broader Picture

GLP-1 therapy is not a replacement for the foundations of metabolic health. It is an accelerant when the foundations are in place and an underused safety net when they are not.

The foundations remain non-negotiable. Resistance training to preserve and build lean mass. Cardiovascular conditioning to improve VO2 max and insulin sensitivity. Adequate protein intake. Sleep restoration. Stress management. Where indicated, hormonal optimization — testosterone, thyroid, estrogen, progesterone — to remove the endocrine headwinds that make metabolic improvement difficult.

A GLP-1 agonist works within this framework. It does not replace it. The patients who do best on GLP-1 therapy are those who use the medication’s appetite suppression to entrench better habits, who train hard enough to keep their muscle, who eat enough protein to fuel recovery, and who reassess regularly with a physician who understands what to look for.

The patients who do worst are those who use GLP-1 therapy as a stand-alone solution, lose muscle along with fat, regain the weight when the medication is discontinued, and arrive a year later metabolically worse than they began.

The medication is powerful. The framework is what makes it medicine.

What to Ask Your Physician

If you are considering GLP-1 therapy in Ontario, several questions move the conversation forward.

What baseline labs and assessments will you order before starting? How will body composition and lean mass be tracked during treatment? What is the protein intake target and the resistance training plan I should follow? What is the monitoring schedule once I am on a stable dose? Is the medication prescribed brand-name or compounded, and why? When and how would treatment be discontinued, and what is the plan to maintain results afterward?

A physician who can answer all of these specifically is practising medicine. A physician who cannot is selling a prescription.

Continue Reading

If you found this useful, these related articles may deepen your understanding:

• What Peptide Therapy Is and Isn’t: A Physician’s Honest Take
• Metabolic Syndrome in Your 40s
• Fasting Insulin: The Test That Should Be Routine

---

Dr. Handsun Xiao is a McGill trained physician (MD, CCFP) practicing functional medicine and bioidentical hormone therapy in Toronto, with virtual consultations available to patients across Ontario. He holds advanced BHRT certification through WorldLink Medical and IFM AFMCP training. Manus Solis offers physician led BHRT consultations with custom compounding through a dedicated Ontario compounding pharmacy partner Trutina. To learn more or book a virtual consultation, visit manussolis.ca.